无张力疝修补术治疗腹股沟嵌顿疝45例体会

目的:探讨无张力疝修补术治疗成人腹股沟嵌顿疝的临床效果。 方法：回顾性分析无张力疝修补术治疗45例腹股沟嵌顿疝患者（包括平片式修补Lichtenstein术12例、疝环充填式Rutkow术31例及经腹股沟切口Kugel腹股沟疝修补术2例）的临床资料。 结果：45例手术过程均顺利。无切口感染和排异反应，无术后死亡。所有患者术后3个月获得门诊随访，未见复发。 结论：无张力疝修补术在治疗成人腹股沟嵌顿疝有良好效果。     

冠状动脉旁路移植手术67例

目的报告2002年4月至2004年12月67例冠状动脉旁路移植手术(CABG).方法男性58例,女性9例,年龄41～76岁,平均58.5岁.合并二尖瓣病变同期手术3例,3支血管病变39例,2支血管病变28例.采取体外循环下手术(on-pump-CABG)和非体外循环下手术(off-pump-CABG)两种方式,各有其适应指征.结果全组死亡1例,其余治愈出院,随诊1～18个月,心绞痛消失,疗效满意.结论冠状动脉旁路移植手术安全,有很好的发展前景.     

脑膜病变MRI异常强化类型与病因的相关性分析

目的 探讨各种脑膜病变脑膜MRI强化类型与病因的关系。方法 回顾性分析78例资料完整，MRI增强扫描脑膜异常强化的非脑膜瘤。结果 78例中，脑膜癌病16例（硬脑膜-蛛网膜型2例，软脑膜-蛛网膜下腔型11例，混合型3例）；感染性脑膜炎18例（硬脑膜-蛛网膜型3例，软脑膜-蛛网膜下腔型13例，混合型2例）；脑梗死22例（软脑膜-蛛网膜下腔型18例，混合型4例）；开颅术后15例（硬脑膜-蛛网膜型10例，混合型5例）；硬膜下积液（血肿）7例，均为硬脑膜-蛛网膜型。结论 MRI双倍剂量Gd-DTPA增强扫描对脑膜病变敏感性高，脑膜强化类型与各种病因侵犯脑膜三层结构的方式和程度有关。     

浅低温心脏不停搏心内手术对心肌保护效果的比较

目的:探讨浅低温体外循环(CPB)心脏搏动中心内直视手术对心肌保护的效果.方法:40例患者随机分为观察组(浅低温心不停搏组)和对照组(中低温心停搏组).分别在术前、转机、停机及术后6 h、12 h、24 h、48 h、72 h,取冠状静脉窦或中心静脉血样,测定血气分析及血清中肌酸磷酸激酶(CK)及其同功酶(CK-MB)、天门冬氨酸氨基转换酶(AST)、乳酸脱氢酶(LDH)、丙二醛(MDA)、超氧化物歧化酶(SOD)的含量.并取心房间隔肌观察心肌含水量及心肌超微结构的改变.临床观察CPB时间、脱机、呼吸支持、多巴胺应用、严重心律失常和血红蛋白尿等指标.结果:冠脉循环血气、电解质、酸碱水平与体循环的组内组间对比基本一致.CK、CK-MB、AST、LDH两组在CPB和术后均有增加,且以对照组升高显著,与观察组相同时点相比,差异均有显著性(P＜0.01).对照组术后MDA明显升高,SOD明显降低(P＜0.01),而观察组变化不大.心肌含水量和超微结构观察,对照组变化显著,而观察组轻微改变.临床指标观察,观察组优于对照组.结论:浅低温体外循环心脏不停搏心内直视手术对心肌损伤很轻,有很好的心肌保护效果.     

Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study

This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53 years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800 mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of 2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening, and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were −3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to 4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5% in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective, placebo-controlled trials. Received: 4 March 2002 / Accepted: 9 July 2002     

石杉碱甲和乙促进小鼠的空间辨别学习和记忆

石杉碱甲和乙是从石杉科石杉属植物蛇足石杉[Huperzia scrrata(Thunb.)Trev.]中分得的二个新生物碱。“Y”迷宫实验表明,ip Hup-A 0.075～0.125 mg/kg或Hup-B 0.4～0.8mg/kg,均能明显促进小鼠的空间辨别学习,并能显著预防CO₂产生的短时识别障碍,促进记忆保持和记忆再现。ig Hup-A 0.1～0.3 mg/kg或Hup-B 0.8 mg/kg也有促进学习的作用。促进作用Hup-A>Phys>Hup-B。剂量与效应曲线呈倒U型。     

Influence of Lung Aeration on Pulmonary Concentrations of Nebulized and Intravenous Amikacin in Ventilated Piglets with Severe Bronchopneumonia

Background: Pulmonary concentrations of aminoglycosides administered intravenously are usually low in the infected lung parenchyma. Nebulization represents an alternative to increase pulmonary concentrations, although the obstruction of bronchioles by purulent plugs may impair lung deposition by decreasing lung aeration.

Methods: An experimental bronchopneumonia was induced in anesthetized piglets by inoculating lower lobes with a suspension of 106 cfu/ml Escherichia coli. After 24 h of mechanical ventilation, 7 animals received two intravenous injections of 15 mg/kg amikacin, and 11 animals received two nebulizations of 40 mg/kg amikacin at 24-h intervals. One hour following the second administration, animals were killed, and multiple lung specimens were sampled for assessing amikacin pulmonary concentrations and quantifying lung aeration on histologic sections.

Results: Thirty-eight percent of the nebulized amikacin (15 mg/kg) reached the tracheobronchial tree. Amikacin pulmonary concentrations were always higher after nebulization than after intravenous administration, decreased with the extension of parenchymal infection, and were significantly influenced by lung aeration: 197 +/- 165 versus 6 +/- 5 [mu]g/g in lung segments with focal bronchopneumonia (P = 0.03), 40 +/- 62 versus 5 +/- 3 [mu]g/g in lung segments with confluent bronchopneumonia (P = 0.001), 18 +/- 7 versus 7 +/- 4 [mu]g/g in lung segments with lung aeration of 30% or less, and 65 +/- 9 versus 2 +/- 3 [mu]g/g in lung segments with lung aeration of 50% or more.     

正常小肠螺旋CT三期扫描技术和方法研究

目的探索正常小肠螺旋CT三期扫描技术和方法的最佳合理配伍关系。方法 80例正常小肠患者 ,随机分为两组 ,按两种配对参数各自进行螺旋CT三期扫描 ,通过双盲法分别选择确定两组显示良好影像质量小肠CT片 ,其中甲组 36例 ,乙组2 5例 ,两组经X2 检验 ,其P 相似文献